Does Preconception Weight Loss Improve Fertility?

Weight loss before fertility treatment may improve metabolic health without improving the outcome most couples care about: bringing home a healthy baby. In the best randomized trial available, an intensive preconception weight-loss program produced a 6.6% average weight loss and reduced metabolic syndrome, yet it did not improve healthy birth outcomes compared with exercise alone.

That result does not mean body weight is irrelevant to fertility or pregnancy. Obesity is associated with hormonal and metabolic changes that can affect ovulation, semen quality, and pregnancy risk. It does mean that "lose weight first, then fertility treatment" is more certain as a piece of clinical folklore than as a live-birth intervention. The method, pace, and reason for weight loss matter.

The trial that tested the assumption

The FIT-PLESE randomized controlled trial enrolled 379 U.S. women with a BMI of at least 30 and unexplained infertility across nine sites. Participants in the intensive group used roughly 1,200 calories per day through meal replacements, took orlistat 60 mg twice daily, and aimed for 10,000 steps daily. The comparison group received the exercise component without the intensive weight-loss program.

The intensive program worked metabolically. Average weight fell 6.6%, and metabolic syndrome prevalence dropped from 52.8% to 32.2%. But the study's primary endpoint was not weight or ovulation. It was a composite healthy birth outcome: a live birth at 37 weeks or later, birth weight of 2,500 to 4,000 grams, and no major congenital anomaly. The groups did not differ significantly on that endpoint.

There was also a safety signal worth taking seriously without overselling it. First-trimester pregnancy loss occurred in 33.3% of pregnancies in the intensive arm and 23.7% in the exercise-only arm. The difference was not statistically significant, so the trial cannot establish that caloric restriction caused miscarriage. Still, the direction matched earlier signals discussed by the investigators and deserves prospective study.

Metabolic improvement and better fertility outcomes are related questions, not interchangeable answers.

FIT-PLESE was open-label, which can introduce performance and detection bias. Its population also matters: participants had confirmed ovulation and unexplained infertility, and the trial excluded women with anovulatory infertility and PCOS. The null result therefore should not be stretched to every person with obesity who is trying to conceive.

Exercise is the least controversial starting point

Exercise looks like the sensible baseline because it can improve cardiometabolic health without requiring aggressive calorie restriction. In FIT-PLESE, exercise alone produced birth outcomes comparable with those of the intensive intervention. A 2024 secondary analysis likewise found that moderate or increased physical activity was not detrimental to live-birth rates among women with unexplained infertility and obesity.

That finding is reassuring, not proof that exercise raises live-birth rates. The study addressed whether activity appeared harmful in this population. It did not demonstrate a fertility benefit from a specific exercise prescription.

A 2025 secondary analysis of a randomized trial found that interdisciplinary care—dietary counseling, activity support, and behavioral coaching—improved lifestyle behaviors in women with obesity and subfertility. Better adherence is useful, but it is not the same as evidence of more pregnancies or births. For couples, a sustainable program that improves food quality, movement, sleep, and metabolic health has a more defensible rationale than a crash diet timed around conception.

PCOS is a different clinical question

Women with PCOS-related anovulation were excluded from FIT-PLESE, and they may have more to gain from lifestyle treatment than the trial participants did. In a 2024 study of women with PCOS and obesity, resumption of ovulation after a six-month lifestyle intervention was associated with lower concentrations of 11β-hydroxyandrostenedione, an androgen metabolite.

This association supports a plausible hormonal pathway: improving metabolic health may help some women resume ovulation as androgen excess falls. It does not prove that the metabolite change caused ovulation, nor does it establish a live-birth benefit. But it is a strong reason not to apply FIT-PLESE as a blanket verdict on anovulatory PCOS.

More weight loss is not automatically better

Bariatric surgery makes the limits of a simple "more weight loss, more fertility" theory hard to ignore. A 2022 systematic review and meta-analysis associated bariatric surgery before conception with higher risks of preterm birth and small-for-gestational-age newborns.

Most evidence in that review came from retrospective registries, with different surgery types and varying intervals between surgery and conception. Those limitations prevent a clean causal claim. Yet the consistent direction of the neonatal signal means bariatric surgery should not be presented as a fertility-optimization shortcut. It may be appropriate for long-term obesity treatment, but pregnancy planning requires individualized counseling, nutritional monitoring, and attention to timing.

The other half of the couple matters

Male obesity also belongs in the fertility conversation. In a cross-sectional study of 226 young men, average age 22.5 years, overweight and obesity were associated with lower total sperm count and concentration, lower testosterone and inhibin B, and higher leptin than normal weight. The 2023 study cannot show that excess weight caused those differences, but it supports the biological case for addressing metabolic health in men.

The strongest intervention evidence comes from an 2022 randomized trial in men with obesity. An eight-week low-calorie diet increased sperm count. At one year, continued exercise or liraglutide, a GLP-1 receptor agonist, maintained that gain. This is encouraging evidence for sperm count, a surrogate marker. The trial did not test pregnancy rates, live birth, sperm DNA fragmentation, motility, morphology, or adverse reproductive effects across the full range of semen measures.

Diet quality may matter independently of calorie reduction. A 2025 systematic review and meta-analysis linked Mediterranean diet adherence in men with better semen quality and medically assisted reproductive outcomes. The evidence supports a pattern rich in minimally processed plant foods, fish, olive oil, and other Mediterranean-style staples; it does not establish that any one food or supplement fixes infertility.

What couples can reasonably do now

A practical preconception plan should aim for durable metabolic health, not a race to a number on the scale. Regular physical activity, a nutrient-dense dietary pattern, and behavioral support have the best balance of evidence and plausibility for both partners. Men may see improved semen parameters with weight loss and sustained exercise, but no controlled trial has shown that a male weight-loss intervention improves live birth.

GLP-1 drugs may help some men maintain diet-induced sperm-count gains, but prospective trials have not tested preconception GLP-1 use against pregnancy or live-birth outcomes in either sex. Anyone using one while planning pregnancy should discuss medication timing and reproductive safety with the prescribing clinician and fertility team rather than treating a sperm-count result as a guarantee.

For women with ovulatory unexplained infertility, delaying fertility treatment solely to pursue intensive calorie restriction has no demonstrated healthy-birth advantage in the highest-quality trial. For women with PCOS-related anovulation, lifestyle treatment may help restore ovulation, but the evidence still does not turn a specific percentage of weight loss into a guaranteed pregnancy outcome. The honest goal is better health entering pregnancy—and clear-eyed decisions about treatment timing.